CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure

Reuters11-12

CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure

CalciMedica Inc. has announced ongoing enrollment in its Phase 2 KOURAGE trial, evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with respiratory failure. The company plans to enroll 150 patients, with data expected in the first half of 2026. Additionally, CalciMedica reported positive discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a pivotal trial in acute pancreatitis $(AP)$, with final trial design anticipated in the first half of 2026. In November 2025, preclinical results on Auxora were presented at the American Society of Nephrology (ASN) Kidney Week, showing improved kidney function and reduced renal injury in a rat model of AKI. CalciMedica has also entered a collaboration with Telperian to utilize AI insights in support of its AP pivotal trial design.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA21933) on November 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582373023?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582373023","market":"fut","top_or_hot":-1,"title":"CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CalciMedica Inc. has announced ongoing enrollment in its Phase 2 KOURAGE trial, evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with respiratory failure. The company plans to enroll 150 patients, with data expected in the first half of 2026. Additionally, CalciMedica reported positive discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a pivotal trial in acute pancreatitis <a href=\"https://laohu8.com/S/AP\">$(AP)$</a>, with final trial design anticipated in the first half of 2026. In November 2025, preclinical results on Auxora were presented at the American Society of Nephrology (ASN) Kidney Week, showing improved kidney function and reduced renal injury in a rat model of AKI. CalciMedica has also entered a collaboration with Telperian to utilize AI insights in support of its AP pivotal trial design.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA21933) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CalciMedica Inc. has announced ongoing enrollment in its Phase 2 KOURAGE trial, evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with respiratory failure. The company plans to enroll 150 patients, with data expected in the first half of 2026. Additionally, CalciMedica reported positive discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a pivotal trial in acute pancreatitis <a href=\"https://laohu8.com/S/AP\">$(AP)$</a>, with final trial design anticipated in the first half of 2026. In November 2025, preclinical results on Auxora were presented at the American Society of Nephrology (ASN) Kidney Week, showing improved kidney function and reduced renal injury in a rat model of AKI. CalciMedica has also entered a collaboration with Telperian to utilize AI insights in support of its AP pivotal trial design.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA21933) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CALC","symbol_name":"CALCIMEDICA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL2Gz9x9:1","article_id":"2582373023","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582373023","pubTimestamp":1762948973,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CalciMedica Inc. has announced ongoing enrollment in its Phase 2 KOURAGE trial, evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury  with respiratory failure. The company plans to enroll 150 patients, with data expected in the first half of 2026. Additionally, CalciMedica reported positive discussions with the U.S. Food and Drug Administration  regarding the design of a pivotal trial in acute pancreatitis , with final trial design anticipated in the first half of 2026. In November 2025, preclinical results on Auxora were presented at the American Society of Nephrology  Kidney Week, showing improved kidney function and reduced renal injury in a rat model of AKI. CalciMedica has also entered a collaboration with Telperian to utilize AI insights in support of its AP pivotal trial design.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-genera","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CALC":"CALCIMEDICA","BK4007":"制药"},"translate_title":"CalciMedica启动Auxora治疗急性肾损伤伴呼吸衰竭的2期KOURAGE试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CALC":0.9},"content_text":"CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure\n    \n\n        CalciMedica Inc. has announced ongoing enrollment in its Phase 2 KOURAGE trial, evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with respiratory failure. The company plans to enroll 150 patients, with data expected in the first half of 2026. Additionally, CalciMedica reported positive discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a pivotal trial in acute pancreatitis $(AP)$, with final trial design anticipated in the first half of 2026. In November 2025, preclinical results on Auxora were presented at the American Society of Nephrology (ASN) Kidney Week, showing improved kidney function and reduced renal injury in a rat model of AKI. CalciMedica has also entered a collaboration with Telperian to utilize AI insights in support of its AP pivotal trial design.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA21933) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582373023","isCrawlerRequest":true}